"BBL's world-class bioanalytical capabilities will strongly complement our current GLP and GMP services, allowing us to better serve our clients in the pharm, biopharm, and device industries," said Tom Spalding, president of Pacific BioLabs. "For example, we can now perform in-house bioanalysis to support PK/ADME studies, medical device material characterizations, and complete ICH stability programs."
Bob Cunico will continue as principal scientist of analytical services at Pacific BioLabs. Mr. Cunico has more than 30 years of experience as an analytical chemist.
Aaron Burke, PBL director of business development, said, "We expect that our clients will be delighted with the expanded technical capabilities of PBL. They will be able to send us more complex and critical studies to better address their needs throughout all phases of development -preclinical, clinical, and post-market. What won't change is the emphasis on fast turnaround time and attentive client service."